← Eichor
Study identifier: NCT06769971 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC

Condition: Small Cell Lung Cancer  ·  Sponsor: Sichuan University

PhasePhase 2
Planned participants80
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This is a phase II study. All patients are treatment naive extensive stage small cell lung cancer(ES-SCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of Ivonescimab and Cadonilimab in combination with chemotherapy in patients with ES-SCLC.

This description comes directly from the study's public registry record.

Talk to the study team

Ge Gao, PhD  ·  86（028）85421606  ·  gg1023@foxmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

West China Hospital, Sichuan UniversityChengdu, Sichuan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06769971